DM
Therapeutic Areas
Fortress Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZYCUBO® (CUTX-101) | Menkes Disease | Marketed |
| UNLOXCYT™ (cosibelimab-ipdl) | Cutaneous Squamous Cell Carcinoma (cSCC) | Marketed |
| Emrosi™ | Rosacea | Marketed |
| Qbrexza® | Primary Axillary Hyperhidrosis | Marketed |
| CAEL-101 | AL Amyloidosis | Phase 3 |
| Dotinurad | Gout & Chronic Kidney Disease | Phase 3 |
| IV Tramadol | Post-Operative Acute Pain | NDA Filed |
| Triplex Vaccine | CMV in Transplant Recipients | Phase 2 |